NeuBase Therapeutics (NBSE) 10-K2018 FY Annual report

Filed: 3 Jan 19, 10:33am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Adele, appeal, appended, Barke, buy, certificate, complaint, constrained, consummation, contemplated, coupled, Dietrich, dissolve, district, divestiture, effectuate, enrichment, expenditure, forward, George, headcount, indemnification, involuntarily, Jeevesh, John, Khanna, kind, LeahySmith, Lehman, loan, maximize, motion, NeuBase, OTC, OTCQB, Panel, PCAOB, penny, Pink, plaintiff, purportedly, quantify, ran, rare, ratio, recover, repealing, requisite, Roth, royalty, Southern, squalimine, stayed, stayedpursuant, Stephan, stipulation, strike, Supreme, sweeping, Tarapowela, timetable, Tomson, unjust, unlisted, vigorously, voluntarily, waste, wholly, wind, wrote

Removed: abandon, aberrant, abnormal, absence, acceptance, achieving, adaptable, advancing, Allegro, Allergan, alternate, altogether, analyzing, anatomical, anticipated, assessing, assessment, assigned, attempt, attracting, Avastin, back, bankruptcy, baseline, begun, bFGF, billion, blood, branch, category, cessation, choroidal, classic, clinically, CNV, collaborate, collected, comfort, commence, component, compound, consisted, controlled, convenience, core, correlated, Correlation, correspondingly, cutoff, daily, damaging, DARPin, deficient, demonstrating, deturgescence, diagnosed, disc, discontinue, disseminated, double, ease, easy, economical, elderly, elevated, encompassed, encounter, endothelial, enhanced, enroll, enrolling, enrollment, European, excluding, existence, expend, exploratory, exudative, Eylea, fewer, fibroblast, field, final, fluid, formation, formulated, formulation, foveal, frequent, grow, guarantee, harmed, hiring, Importantly, improved, incidence, inconclusive, incurrence, inhibiting, inhibition, injection, injunction, institutional, integrin, intracellular, intravitreal, investigated, investigation, investigational, investigator, irreversibly, IST, kinase, lactate, leaky, lease, lesion, manufactured, manufacturer, marketable, masked, meaningfully, mechanism, minimize, molecule, monetizing, monotherapy, multiple, negotiation, NEI, neovascularization, nominated, nonrenewal, obligated, occlusion, occult, OCT, offsetting, older, Ophthotech, optimal, optimized, oral, path, PDGF, PDR, people, peptide, pharmacodynamic, pharmacokinetic, pharmacology, placebo, point, population, predictive, predictor, presence, presented, prespecified, prevalence, prevented, PRN, project, proliferative, proportion, prospective, protein, proximity, publication, randomized, randomly, readout, recoup, regimen, regressed, regression, released, renewal, Rental, rented, replicate, replicated, returned, route, sample, satisfactorily, satisfactory, screening, showing, side, size, solution, SPA, space, standard, submission, subset, suit, superior, supplemental, supplier, susceptible, target, targeting, therapy, timeframe, timeline, topical, toxicology, tree, Tyrogenex, tyrosine, unavailable, undermine, underway, Union, unreported, unsuccessful, uptake, utilizing, vast, VEGF, vein, vision, week, wet, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Ohr Pharmaceutical, Inc. 10-K

Exhibit 32.2

Certification of Chief Financial Officer
Pursuant to 18 U.S.C Section 1350,
As Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002

Not Filed Pursuant to the Securities Exchange Act of 1934

In connection with the Annual Report of Ohr Pharmaceutical, Inc. (the“Company”) on Form 10-K for the fiscal year ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the“Report”), I, Sam Backenroth, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 3, 2019

/s/ Sam Backenroth

Sam Backenroth, Chief Financial Officer

(Principal Financial and Accounting Officer)